TITLE

Insulin degludec in Phase 3 trials

AUTHOR(S)
Elliott, William T.
PUB. DATE
May 2011
SOURCE
Internal Medicine Alert;5/15/2011 Supplement, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the phase 3 trials of insulin degludec, a ultralong-acting insulin, from Novo Nordisk A/S.
ACCESSION #
62093058

 

Related Articles

  • NovoLog (insulin aspart [rDNA origin] injection) Novo Nordisk.  // Clinician Reviews;Mar2007, Vol. 17 Issue 3, p52 

    The article evaluates the Novolog® insulin aspart injection from Novo Nordisk.

  • Novo says no to Lilly's insulin.  // Drug Topics;8/19/96, Vol. 140 Issue 16, p8 

    Details a letter issued by Novo Nordisk Pharmaceuticals to pharmacists recommending against the use of Eli Lilly manufactured Humulin insulin cartridges with NovoPen 1.5. Approval by Food & Drug Administration on use of NovoPen 1.5 with Novolin PenFill insulin cartridges.

  • Lilly suffers another bruise from Novo.  // Indianapolis Business Journal;3/14/2011, Vol. 32 Issue 2, p13A 

    The article reports on Novo Nordisk A/S scoring a victory against its rival Eli Lilly and Co. in the diabetes business and maintained its global insulin market share in the U.S.

  • Your Complete Insulin Reference Guide From Diabetes Health.  // Diabetes Health;Jun2004, Vol. 13 Issue 6, p56 

    Presents a complete insulin reference guide for people with diabetes. Humalog Vial from Lilly; NovoLog PenFill from Novo Nordisk; Lantus Vial from Aventis.

  • NNE injects insulin capacity. Whitfield, Mark // European Chemical News;8/4/2003, Vol. 79 Issue 2064, p29 

    Reports on the completion of a production plant for the manufacture and purification of insulin by Novo Nordisk Engineering (NNE) at Kalundborg in Copenhagen, Denmark in 2003. Areas of production; Importance of extra manufacturing capacity; Statement issued by Ole Regnar Hansen, project...

  • Long-Acting Levemir Now Available. Trecroci, D. // Diabetes Health;Jun2006, Vol. 15 Issue 6, p36 

    This article reports on the approval by the U.S. Food and Drug Administration of the long-acting insulin Levemir from Novo Nordisk Inc. With this approval Novo Nordisk has become the second company with both a rapid- and long-acting insulin. Levemir become commercially available in the country...

  • Levemir Pregnancy Change.  // MPR - Obstetrician & Gynecologist Edition;Spring/Summer2012, Vol. 23 Issue 1, p7 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved Novo Nordisk A/S' Levemir insulin for a pregnancy Category B classification.

  • Marketing in diabetes focuses on better control. M. I. // Medical Marketing & Media;May2011, Vol. 46 Issue 5, p9 

    The article reports on the Drive the Switch marketing campaign of Novo Nordisk A/S which promotes insulin delivery options to control of diabetes in the U.S.

  • Victoza Labeling Updated.  // Monthly Prescribing Reference;May2012, Vol. 28 Issue 5, pA-8 

    The article offers information that the product labeling of Victoza, a GLP-1 receptor agonist, from Novo Nordisk A/S has been updated which includes a data demonstrating the safety and efficacy of adding basal insulin to Victoza and metformin for the treatment of adults with type II diabetes.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics